Skip to content

Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma

Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06543030
Enrollment
60
Registered
2024-08-07
Start date
2024-08-31
Completion date
2025-12-31
Last updated
2024-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma

Detailed description

To compare transfemoral approach (TFA) and transradial approach (TRA) in patients undergoing hepatic chemoembolization in terms of safety, feasibility, and procedural variables, including fluoroscopy time and patient preference.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Patients with Hepatocellular carcinoma of BCLC (Barcelona Clinic Liver Cancer) stage B * Also for BCLC stage A patients, in whom ablative therapy has technical limitations. * Downsizing tumor for resection or transplantation.

Exclusion criteria

* Factors related to liver cirrhosis: * Decompensated cirrhosis (Child-Pugh B and C, score \>8), including jaundice, clinical hepatic encephalopathy, and refractory ascites and/ or hepatorenal syndrome * Impaired portal-vein blood flow (portal-vein thrombus, hepatofugal blood flow) * Factors related to HCC: * Extensive tumor involving the entirety of both lobes of the liver * Malignant portal vein thrombosis * Extra-hepatic metastases * Impaired renal function: * Creatinine ≥2 mg/dl or creatinine clearance \<30 ml/min * Factors related to procedure (Radial artery access): * Existing AV (arteriovenous) fistula or graft * Pervious major surgery to forearm or wrist * Vasculitis * Pervious access failure * Skin infection or compromised integrity * Artery size \<2mm * Intolerance of hyperextended wrist positioning * Severe vasospasm * Vessel tortuosity * Radial loops * Absent or occluded radial artery * Atherosclerotic or calcific PAD (peripheral artery disease) * Coagulopathy INR\>1.5 platelets count \<50.000/mmc

Design outcomes

Primary

MeasureTime frameDescription
To compare transfemoral approach (TFA) and transradial approach (TRA) in patients undergoing hepatic chemoembolizationBaselineTo compare transfemoral approach (TFA) and transradial approach (TRA) in patients undergoing hepatic chemoembolization in terms of safety, feasibility, and procedural variables, including fluoroscopy time and patient preference.

Countries

Egypt

Contacts

Primary ContactAli AA Sewisy, M.B.B.CH
aliadelsewisy@yahoo.com+201142606214

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026